The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 10, 2019
Filed:
Jan. 30, 2018
Applicant:
Chiesi Farmaceutici S.p.a., Parma, IT;
Inventors:
Alessandro Accetta, Parma, IT;
Fabio Rancati, Parma, IT;
Anna Maria Capelli, Parma, IT;
David Edward Clark, Saffron Walden, GB;
Patrizia Tisselli, Saffron Walden, GB;
Christine Edwards, Saffron Walden, GB;
Gurdip Bhalay, Saffron Walden, GB;
Arnaud Jean Francois Auguste Cheguillaume, Saffron Walden, GB;
Assignee:
CHIESI FARMACEUTICI S.P.A., Parma, IT;
Primary Examiner:
Int. Cl.
CPC ...
C07D 471/04 (2006.01); A61K 9/00 (2006.01); A61K 31/437 (2006.01); A61K 31/4375 (2006.01); A61K 31/439 (2006.01); A61K 31/444 (2006.01); A61K 31/4725 (2006.01); A61K 31/496 (2006.01); A61K 31/498 (2006.01); A61K 31/4985 (2006.01); A61K 31/501 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/5383 (2006.01); C07D 471/08 (2006.01); C07D 498/04 (2006.01); C07D 487/04 (2006.01); C07D 519/00 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61K 9/0073 (2013.01); A61K 31/437 (2013.01); A61K 31/439 (2013.01); A61K 31/4375 (2013.01); A61K 31/444 (2013.01); A61K 31/4725 (2013.01); A61K 31/496 (2013.01); A61K 31/498 (2013.01); A61K 31/4985 (2013.01); A61K 31/501 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/5383 (2013.01); C07D 471/08 (2013.01); C07D 487/04 (2013.01); C07D 498/04 (2013.01); C07D 519/00 (2013.01);
Abstract
Tyrosine amide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).